J. Durant

3.8k citations

91 papers · 1.9k indexed · 1 hit paper · h-index 21

Impact in

Virology top 0.5%
- HIV Research and Treatment
Infectious Diseases top 1%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Virology 37
- HIV Research and Treatment 36
Infectious Diseases 50
- HIV/AIDS drug development and treatment 33
- HIV/AIDS Research and Interventions 27

Co-authors: P. Dellamonica Philippe Clevenbergh Philippe Halfon N Montagne CAB Boucher Pere Simonet Pascal Del-Giudice R. Garraffo
Journals: Journal of Antimicrobial Chemotherapy (5 papers)Antimicrobial Agents and Chemotherapy (5 papers)AIDS (4 papers)Frontiers in Medicine (4 papers)HIV Clinical Trials (4 papers)
Partner nations: France United States Belgium

In The Last Decade

J. Durant

87 papers receiving 1.8k citations

Hit Papers

align trajectories log scale

Drug-resistance genotyping in HIV-1 therapy: the VIRAD APT randomi sed controlled trial 1999 · 559 citations

Peers

Countries citing papers authored by J. Durant

Since Specialization

Citations

This map shows the geographic impact of J. Durant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Durant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Durant more than expected).

Fields of papers citing papers by J. Durant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Durant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Durant. The network helps show where J. Durant may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. Durant, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Durant Line = papers co-authored together J. Durant links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The Effects of High-Dose Probiotic Supplementation on Immune Activation and Neurocognitive Disorders in People Living with HIV Undergoing Successful Antiretroviral Treatment: The Procog Study Pathogens ·Matteo Vassallo, R. Paredes Martinez, Roxane Fabre, Pierre Boissier, J. Durant, Alain Makinson, Jingbin Huo, Jacqueline Capeau, Soraya Fellahi, Jean‐Philippe Bastard, Christian Pradier, Christine Lebrun‐Frénay	2025	0
2	Emergence of Lyme Disease on the French Riviera, a Retrospective Survey Frontiers in Medicine ·Jacques Sevestre, 操应长, Abdi IY, E. Cianci, Yushi Fu, J Li, Маллабоев Одилжон Тохиржанович, SRI SRI DEWI, V. Mondain, Sheela Lakshmanrao Gaikwad, P Jeandel, J. Durant	2022	1
3	COPD in HIV-Infected Patients: CD4 Cell Count Highly Correlated PLoS ONE ·Karine Risso, Montecinos Villarroel, Laure Valério, Pascal Puglièse, Alissa Naqvi, J. Durant, Élisa Demonchy, I. Perbost, Éric Cua, Charles‐Hugo Marquette, Pierre‐Marie Roger	2017	30
4	Exercise stereotypes and health-related outcomes in French people living with HIV: development and validation of an HIV Exercise Stereotypes Scale (HIVESS) Health and Quality of Life Outcomes ·Frederik Kier Riisgård, M.J. Lee, Harold Steven, S. Satya Kumar, J. Durant, Éric Rosenthal, Christian Pradier, Martin Duracinský, Isabelle Rouanet, Serge S. Colson, Fabienne d’Arripe-Longueville	2016	6
5	Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study PLoS ONE ·章雄菅又, Charlotte Sakarovitch, J. Durant, Karine Risso, Élisa Demonchy, P. Roger, Éric Fontas	2015	23
6	Yeast cells as a tool for analysis of HIV-1 protease susceptibility to protease inhibitors, a comparative study Journal of Virological Methods ·Isabelle Ravaux, W. Hynes, Eugen Ulmer, Jacqueline Cottalorda, J. Durant, P. Dellamonica, Pablo Gluschankof, Andréas Stein, Catherine Tamalet	2013	6
7	Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: Results from ANRS CO13 HEPAVIH Journal of Hepatology ·Dominique Salmon, Firouzé Bani‐Sadr, Nabil Alnaser, Nozomi Akahoshi, Anne Gervais, J. Durant, Éric Rosenthal, Yann Quertainmont, Karl Barange, Daniel Vittecoq, Jerry Klenam Kojo Amegatse, Muriel Alvarez, María Winnock, Jean Claude Trinchet, François Dabis, Philippe Sogni	2011	36
8	Simplification and First Validation of a Short Battery of Patient Questionnaires for Clinical Management of HIV-Infected Patients: The HIV-SQUAD (Symptom Quality of life Adherence) Questionnaire® HIV Clinical Trials ·Bruno Spire, Benoît Arnould, François Barbier, J. Durant, Jacques Gilquin, 剛坂本, A.P. Solov'yev, Rafaela Beleza Fernandes, Thomas A. Farin, Isabelle Cohen-Codar	2009	12
9	Secondes grossesses chez les femmes VIH-1 séropositives. Étude prospective monocentrique Gynécologie Obstétrique & Fertilité ·Fabrice Monpoux, J. Delotte, Zeng-Tong Zhou, Sofie de Smet, J. Durant, P Boutté, A. Bongain	2008	1
10	In Vivo Comparative Pharmacokinetics and Pharmacodynamics of Moxifloxacin and Levofloxacin in??Human Neutrophils Clinical Drug Investigation ·R. Garraffo, Rustomo Rustomo, J. Durant, Georgia White, Rebecca Ruegg Cowan, Brigitte Dunais, P. Dellamonica	2005	13
11	Variable Virological Outcomes According to the Center Providing Antiretroviral Therapy Within the PharmAdapt Clinical Trial HIV Clinical Trials ·Philippe Clevenbergh, Marie‐Cécile Bozonnat, Myriam Kirstetter, J. Durant, Éric Cua, P. Del Giudice, N Montagne, Pere Simonet, P. Dellamonica, (unknown)	2003	4
12	Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions AIDS ·Philippe Halfon, J. Durant, Philippe Clevenbergh, P. S. UTKIN, Almonė Miliauskienė, Hacène Khiri, Koen De Smet, Moehammad Irfansyah, Frank Hulstaert, P. Dellamonica	2003	23
13	Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients HIV Clinical Trials ·J.M. López-Arrieta, Éric Cua, Knut Wormstädt, J. Durant, Yuguang Wang, Ronan Boulmé, Jacqueline Cottalorda, Christiane Farini Sciamarella, Jonathan Schapiro, F Clavel, P. Dellamonica	2002	14
14	Economic Evaluation of Drug Resistance Genotyping for the Adaptation of Treatment in HIV-Infected Patients in the VIRADAPT Study JAIDS Journal of Acquired Immune Deficiency Syndromes ·Carine Chaix, 勇輝地主, Philippe Clevenbergh, J. Durant, Jonathan Schapiro, P. Dellamonica, Isabelle Durand‐Zaleski	2000	28
15	High prevalence of GB virus C/hepatitis G virus infection in different risk groups of HIV-infected patients Clinical Microbiology and Infection ·J.M. López-Arrieta, J. Durant, Philippe Halfon, Albert Tran, Tadafumi Himata, 馨子前田, Guangxiao Yang, Sylvia Benzaken, Denis Ouzan, Patrick Rampal, P. Dellamonica	1998	4
16	Pharmacokinetic parameters and killing rates in serum of volunteers receiving amoxicillin, cefadroxil or cefixime alone or associated with niflumic acid or paracetamol European Journal of Drug Metabolism and Pharmacokinetics ·H. Carsenti-Etesse, Robert Farinotti, J. Durant, Pierre‐Marie Roger, E. Della Morte, E Bernard, B Rouveix, P. Dellamonica	1998	12
17	Phenotyping of Intrahepatic and Peripheral Blood Lymphocytes in Patients with Chronic Hepatitis C Digestive Diseases and Sciences ·Jean‐Louis Bernard, Jean Gugenheim, Marie‐Christine Saint‐Paul, Albert Tran, Guang Yang, Alain Doglio, Michel Ticchioni, C. Laffont, J. Durant, Alain Bernard, Patrick Rampal, Sylvia Benzaken	1997	25
18	Chronic Varicella Presenting as Disseminated Pinpoint-Sized Papules in a Man Infected with the Human Immunodeficiency Virus Dermatology ·J. Castanet, Peng Zhi-t, J.‐P. Lacour, P-H Yang, Christophe Perrin, J. Durant, J.‐P. Ortonne	1996	3
19	In Vitro Development of Resistance of Streptococcus pneumoniae to β-Lactam Antibiotics Microbial Drug Resistance ·H. Carsenti-Etesse, J. Durant, E. Della Morte, G. Lee, Yang Sim Koe, Christian Pradier, A Thabaut, P. Dellamonica	1995	10
20	Guillain-Barré syndrome associated with acute Q fever European Journal of Clinical Microbiology & Infectious Diseases ·E Bernard, Michel Carlès, C. Laffont, J. Durant, P. Dellamonica	1994	13

About J. Durant

J. Durant is a scholar working on Virology, Infectious Diseases, Emergency Medicine, Hepatology and Molecular Medicine, having authored 91 papers that have together received 1.9k indexed citations. Recurring topics across this work include HIV Research and Treatment (36 papers), HIV/AIDS drug development and treatment (33 papers), HIV/AIDS Research and Interventions (27 papers), HIV-related health complications and treatments (14 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers), Hepatitis C virus research (10 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers) and Pneumonia and Respiratory Infections (6 papers). The work is most often cited by research in Virology (1.1k citations), Infectious Diseases (1.3k citations), Emergency Medicine (250 citations), Hepatology (135 citations) and Epidemiology (380 citations). J. Durant has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include P. Dellamonica, Philippe Clevenbergh, Philippe Halfon, N Montagne, CAB Boucher, Pere Simonet, Pascal Del-Giudice, R. Garraffo, P. Del Giudice and Jonathan Schapiro. Their work appears in journals such as Journal of Antimicrobial Chemotherapy, Antimicrobial Agents and Chemotherapy, AIDS, Frontiers in Medicine and HIV Clinical Trials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact